Search peptides, terms, sources/
Research source · 2019

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder, Two Randomized Phase 3 Trials

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
Human, premenopausal women with HSDD, two trials, combined n approximately 1247, multicentre
Sample size
approximately 1247 (combined)
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Industry-sponsored (Palatin Technologies); disclose as a conflict-of-interest factor. Otherwise the strongest-designed human evidence identified in this batch.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.